Recent Updates
Recently added Catalysts
VKTX Positive Sentiment

Brandon D. Porter, Esq., M.B.A

Key Takeaway: Brandon D. Porter has been appointed as Vice President of Regulatory Affairs at Viking. With over 20 years of experience in the pharmaceutical and biotechnology sectors, he has a proven track record in regulatory strategy. Previously, he served as Executive Director at Protagonist Therapeutics and has held key roles at major companies like Pfizer and Janssen, where he contributed to multiple FDA drug approvals.
Price reaction · baseline $33.75 (2026-02-24 close) · hit pre-market · clean, no other VKTX news in the window
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Brandon D. Porter has over 20 years of industry experience.
  • He has successfully led regulatory strategies for multiple companies.
  • Instrumental in obtaining FDA approvals for several new drugs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

Mr. Porter serves as our Vice President of Regulatory Affairs. He has over 20 years of experience in the pharmaceutical and biotechnology industry. He is a California licensed attorney with an M.B.A. and J.D. from the University of Kansas. Prior to joining Viking, he was the Executive Director of Regulatory Affairs at Protagonist Therapeutics, where he was responsible for developing and executing the company’s regulatory strategy and preparing the company to file its first new drug application (NDA). Prior to Protagonist, he has been the regulatory lead for programs at Pfizer, Arena Pharmaceuticals, Janssen Research and Development, and Inovio Biomedical. He was instrumental in filing and obtaining FDA approval for multiple new drugs at Janssen, including the first-in-class diabetes drug Invokana (canagliflozin) and two fixed dose combinations with canagliflozin and metformin (Invokamet and Invokamet XR). His experience includes small molecules, peptides, and biologics and all phases of clinical development.

Frequently Asked Questions

What is Brandon D. Porter's role at Viking?

He serves as the Vice President of Regulatory Affairs.

How many years of experience does Brandon D. Porter have?

He has over 20 years of experience in the industry.

Where did Brandon D. Porter work before Viking?

He was the Executive Director of Regulatory Affairs at Protagonist Therapeutics.

What notable drug approvals was Porter involved in?

He contributed to the FDA approvals of Invokana and its combinations.

Last updated: Feb 25, 2026